How DCN Dx Helped a Diagnostics Startup Improve Performance and Rethink Its Path to Market
This case study explores how a diagnostics startup, confident their lateral flow assay was ready for manufacturing, ran into pushback from their CDMO—and turned to DCN Dx for answers. What followed was a hard look at performance, clinical value, and long-term viability.
DCN Dx conducted a full technical evaluation, identified core deficiencies, and increased assay sensitivity by 15%. But the deeper impact came from a strategic reassessment: DCN Dx’s findings revealed questions about the analyte’s clinical relevance, prompting the client to rework their product strategy before committing further resources.
For any startup navigating early-stage product development, this case offers a clear look at how technical transparency and expert collaboration can shape smarter paths forward.
WHY READ
This case study is essential for diagnostics startups facing early development uncertainty. You’ll learn how DCN Dx helped:
- Identify fundamental issues in an assay initially deemed manufacturing-ready.
- Increase sensitivity and troubleshoot critical performance gaps.
- Complete feasibility and Phase 2 development under a compressed timeline.
- Consult on strategic product direction based on clinical validation insights.
- Prevent wasted investment by addressing performance and market-fit issues early.
